Sage Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge United Kingdom (2010)

Organization Overview

First Clinical Trial
2014
NCT02052739
First Marketed Drug
2019
brexanolone (Zulresso)
First NDA Approval
2019
brexanolone (Zulresso)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Sage Bionetworks | SAGE THERAP | Sage Therapeutics